JP2012504551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504551A5 JP2012504551A5 JP2011514137A JP2011514137A JP2012504551A5 JP 2012504551 A5 JP2012504551 A5 JP 2012504551A5 JP 2011514137 A JP2011514137 A JP 2011514137A JP 2011514137 A JP2011514137 A JP 2011514137A JP 2012504551 A5 JP2012504551 A5 JP 2012504551A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- dosage form
- pharmaceutical dosage
- unit
- form according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 23
- 239000002552 dosage form Substances 0.000 claims 15
- 239000011159 matrix material Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 229920006037 cross link polymer Polymers 0.000 claims 4
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 210000004051 gastric juice Anatomy 0.000 claims 3
- 239000001814 pectin Substances 0.000 claims 3
- 235000010987 pectin Nutrition 0.000 claims 3
- 229920001277 pectin Polymers 0.000 claims 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 239000000227 bioadhesive Substances 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 238000005187 foaming Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 1
- 229960000564 nitrofurantoin Drugs 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200710997 | 2008-06-19 | ||
| ZA2007/10997 | 2008-06-19 | ||
| PCT/IB2009/005828 WO2009153632A1 (en) | 2008-06-19 | 2009-06-03 | A gastroretentive pharmaceutical dosage form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504551A JP2012504551A (ja) | 2012-02-23 |
| JP2012504551A5 true JP2012504551A5 (OSRAM) | 2012-09-06 |
| JP5560268B2 JP5560268B2 (ja) | 2014-07-23 |
Family
ID=44309136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514137A Expired - Fee Related JP5560268B2 (ja) | 2008-06-19 | 2009-06-03 | 胃保持型医薬剤形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8778396B2 (OSRAM) |
| EP (1) | EP2306983A1 (OSRAM) |
| JP (1) | JP5560268B2 (OSRAM) |
| WO (1) | WO2009153632A1 (OSRAM) |
| ZA (1) | ZA200903854B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102307574A (zh) * | 2008-10-08 | 2012-01-04 | 鲍斯生命科学Pvt有限公司 | 缓释给药系统 |
| WO2011053917A2 (en) * | 2009-11-01 | 2011-05-05 | Adeona Pharmaceuticals, Inc. | Gastroretentive oral high dose zinc preparations |
| EP2444064A1 (en) * | 2010-10-22 | 2012-04-25 | Meliatys | Process for making multiparticulate gastroretentive dosage forms |
| US8589775B2 (en) * | 2011-03-14 | 2013-11-19 | Infineon Technologies Ag | Error tolerant flip-flops |
| CN104666267B (zh) * | 2015-03-27 | 2017-08-08 | 康普药业股份有限公司 | 一种阿昔洛韦药物组合物 |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| CN109310653A (zh) | 2016-03-17 | 2019-02-05 | 硫创治疗公司 | 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物 |
| ES3024932T3 (en) | 2017-09-20 | 2025-06-05 | Thiogenesis Therapeutics Inc | Compounds for the treatment of cysteamine sensitive disorders |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| AU2018388577B2 (en) * | 2017-12-18 | 2024-06-06 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
| CA3085941A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| US10835489B2 (en) | 2018-03-09 | 2020-11-17 | University Of Saskatchewan | Modified release formulations of mycophenolate mofetil |
| KR20210031910A (ko) * | 2018-06-19 | 2021-03-23 | 싱가포르국립대학교 | 다양한 적응증에 대한 향상된 생체 이용률을 위한 5-하이드록시트립토판의 제형 |
| CN109925289B (zh) * | 2019-04-11 | 2021-05-25 | 海南普利制药股份有限公司 | 地氯雷他定分散片 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
| EP4362919A1 (en) | 2021-07-30 | 2024-05-08 | Evecxia Therapeutics, Inc. | 5-hydroxytryptophan gastroretentive dosage forms |
| US12409163B2 (en) | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| JP2024535585A (ja) | 2021-10-14 | 2024-09-30 | エヴェクシア セラピューティクス， インク． | 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| NZ523747A (en) * | 1998-09-14 | 2004-04-30 | Ranbaxy Lab Ltd | Pharmaceutical composition comprising a drug, a gas generating component, a swelling agent, a viscolyzing agent and a gel forning polymer |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| AU2002363998A1 (en) * | 2001-12-15 | 2003-06-30 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
| US20070196396A1 (en) | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| WO2005084639A2 (en) * | 2004-03-03 | 2005-09-15 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
| MX2008000099A (es) * | 2005-06-29 | 2008-03-19 | Panacea Biotec Ltd | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. |
| WO2007106957A1 (en) | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
| US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
-
2009
- 2009-05-29 ZA ZA2009/03854A patent/ZA200903854B/en unknown
- 2009-06-03 US US12/999,914 patent/US8778396B2/en not_active Expired - Fee Related
- 2009-06-03 WO PCT/IB2009/005828 patent/WO2009153632A1/en not_active Ceased
- 2009-06-03 EP EP09766174A patent/EP2306983A1/en not_active Withdrawn
- 2009-06-03 JP JP2011514137A patent/JP5560268B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504551A5 (OSRAM) | ||
| JP2013544259A5 (OSRAM) | ||
| Prinderre et al. | Advances in gastro retentive drug-delivery systems | |
| Abdul et al. | A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS) | |
| CA2828747C (en) | Porous disintegratable solid substrate for personal health care applications | |
| JP5534004B2 (ja) | 口腔内崩壊錠 | |
| JP2011037876A5 (OSRAM) | ||
| JP2013512250A5 (OSRAM) | ||
| JP2003514845A (ja) | 胃内滞留性制御放出医薬剤形 | |
| JP2003514845A5 (OSRAM) | ||
| EP2068844A2 (en) | Programmable buoyant delivery technology | |
| TW201127375A (en) | Taste masked topiramate composition and an orally disintegrating tablet comprising the same | |
| JPWO2011118453A1 (ja) | 固形製剤 | |
| CN103784414B (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
| JP2011525501A5 (OSRAM) | ||
| WO2005097080A1 (ja) | 経口投与剤 | |
| CN103228676A (zh) | 羟烷基纤维素 | |
| CN113521029A (zh) | 包含富马酸二甲酯的药物珠粒制剂 | |
| KR20110130441A (ko) | 고형 제제 | |
| JPWO2011121823A1 (ja) | 経口投与用粒子状医薬組成物 | |
| US20090202630A1 (en) | Orally disintegrating tablet compositions of ranitidine and methods of manufacture | |
| CN101862305A (zh) | 一种盐酸氨溴索缓释微丸及制备方法 | |
| CN105188683A (zh) | 控释药物剂型 | |
| US9119793B1 (en) | Gastroretentive dosage forms for doxycycline | |
| CN110461310A (zh) | 用于使用射频和有损耗的包衣粒子制备片剂的方法 |